PF-06821497, Docetaxel, Enzalutamide — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-07-13 in 21d
ESTIMATED |
READOUT
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevromet
Phase 3 · Metastatic Castrate Resistant Prostate Cancer (mCRPC) |
PFE PFIZER INC | PF-06821497, Docetaxel, Enzalutamide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|